Chronic Hand Eczema

Click here to answer our poll.

Explore innovative strategies for managing chronic hand eczema, focusing on personalized care, early treatment, and understanding complex subtypes for better outcomes.

A study reveals the significant emotional burden of work-related chronic hand eczema, highlighting the need for tailored psychological support for affected patients.

Global studies from LEO Pharma highlight the diagnostic gaps, quality-of-life burdens, and treatment landscape for patients with CHE.

At the Fall Clinical PA/NP 2025 Conference, attendees caught up on the ins and outs of CHE.

Chronic hand eczema poses diagnostic challenges and impacts quality of life, but emerging JAK inhibitors offer promising new treatment options.

Christopher G. Bunick, MD, PhD, presents the significant challenges of CHE due to a lack of FDA-approved treatments, impacting patients' quality of life and requiring better therapeutic options.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

This review of the latest dermatologic studies includes insights into chronic hand eczema, including self-reported severity, burden of pain and use of analgesics, and more.

Explore the evolving landscape of self-reported hand eczema severity assessments, highlighting their potential and challenges in clinical research and digital health.

We review survey data revealing diagnostic confusion, treatment gaps, and the emotional, social, and occupational toll of moderate to severe chronic hand eczema.

Our May cover story explores NIH’s new findings on topical steroid withdrawal, a condition now under scientific scrutiny as a distinct entity.

Delgocitinib cream significantly enhances health-related quality of life for patients with chronic hand eczema, addressing both symptoms and psychosocial impacts.

Omar Noor, MD, FAAD, explores the complex immune and cellular mechanisms behind CHE and highlights its significant physical and emotional toll on patients.

A survey by LEO Pharma indicates widespread misunderstandings about chronic hand eczema, revealing significant emotional and occupational challenges for patients.

The company also announced in a press release that the product received the Seal of Acceptance by the NEA.

Patients reported the face, neck, and inner arms as the most affected body regions before treatment.

Hand eczema affects 22.4% of adults in East Greenland, with prevalence, severity, and risk factors mirroring trends other populations.

Patients with CHE saw higher treatment success and a favorable safety profile with delgocitinib 20-30 mg/g.

Participants from the parent DELTA 1 and 2 studies maintained their disease control and observed a decrease in pain and itch over 52 weeks of treatment.

JiaDe Yu, MD, discussed important clinical issues in allergic contact dermatitis at the AAD Annual Meeting.

A new survey reveals widespread misunderstanding and lack of effective treatments in chronic hand eczema.

DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.

The phase 3 clinical trial investigating delgocitinib cream for adolescents with moderate to severe CHE met its primary and key secondary endpoints.

The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in chronic hand eczema this year.

Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.

The study found that those who worked with wet hands and had chapped skin had a higher severity of chronic hand eczema.

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.